secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0000950170-23-047585
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences unveils mitoARCUS program PBGENE-PMM; HBV program on track for 2024 filing
--------------------------------------------------------------------------------

- Announced PBGENE-PMM, first mitoARCUS candidate targeting m.3243 primary mitochondrial myopathy; CTA/IND submission targeted for 2025.
- Lead PBGENE-HBV for chronic hepatitis B on track for CTA/IND in 2024; data shows potential to eliminate cccDNA and integrated HBV DNA.
- PBGENE-NVS with Novartis aims for in vivo transgene insertion for sickle cell and beta thalassemia; PBGENE-DMD with Lilly subsidiary excises ~500k base pair dystrophin hot spot.
- Partner iECURE-OTC for OTC deficiency showed >20% gene insertion efficiency at 12 months; CTA/IND submission targeted for 2023.
- Company highlights ARCUS platform advantages: unique cut, size, simplicity enabling viral/mitochondrial genome elimination, gene excision, and insertion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023047585/0000950170-23-047585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023047585/dtil-20230912.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer